In light of an Indian court’s refusal to grant a patent to the leukemia drug Gleevec, CFR senior fellow Thomas Bollyky wrote yesterday about the tension between pharmaceutical firms seeking compensat…

Each Friday, I look at what the presidential contenders are saying about foreign policy. This Week: China is following Russia’s lead in meddling in the U.S. presidential election.

In an article yesterday on CNN, CFR senior fellow Thomas Bollyky surveyed the tension between two leading global health concerns: protecting pharmaceutical firms’ intellectual property (IP) and impro…